What is AlloVir, Inc. (ALVR) stock price today?

AlloVir, Inc. (ALVR) is currently trading at $9.81, up 4.14% today.

What is ALVR P/E ratio?

AlloVir, Inc.'s P/E ratio is -1.89. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ALVR return on equity (ROE)?

AlloVir, Inc.'s return on equity (ROE) is -72.78%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is AlloVir, Inc.'s market cap?

AlloVir, Inc. has a market capitalization of $49.48M.

NASDAQ · Biotechnology

AlloVir, Inc. (ALVR) Stock

$9.81 +4.14% NASDAQ: ALVR Healthcare

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies.

Valuation

Metric	Value
Price	$9.81
Market Cap	$49.48M
P/E Ratio	-1.89
P/B Ratio	1.41
P/S Ratio	0.00
EPS (TTM)	$-2.85
52-Week High	$24.15
52-Week Low	$7.96
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-72.78%
ROA	-40.16%
ROCE	-46.82%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	12.14

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-170.0M	$-171.0M	$-181.0M	$-65.0M	$-46.0M
Net Profit	$-172.0M	$-169.0M	$-190.0M	$-59.0M	$-43.0M
EPS	$-63.02	$-50.60	$-42.09	$-11.73	$-2.85
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$287.0M	$277.0M	$191.0M	$119.0M	$122.0M
Total Liabilities	$61.0M	$53.0M	$45.0M	$5.0M	$43.0M
Cash	$202.0M	$106.0M	$90.0M	$118.0M	$98.0M
Borrowings	$30.0M	$35.0M	$27.0M	$0	$1.0M

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-106.0M	$-142.0M	$-124.0M	$-68.0M	$-38.0M
Investing Cash Flow	$186.0M	$-80.0M	$38.0M	$95.0M	$-20.0M
Financing Cash Flow	$0	$1.0M	$0	$0	$155.0M
Net Cash Flow	$80.0M	$-96.0M	$-16.0M	$27.0M	$97.0M
Free Cash Flow	$-106.0M	$-142.0M	$-124.0M	$-68.0M	$-39.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-0.98
FCF Yield	-64.48%
Quick Ratio	12.14
Interest Coverage	-46.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHLAchilles Therapeutics plc	$1.48	+0.68%	-0.85	$60.83M	0.00%
BLUEbluebird bio, Inc.	$4.97	—	-0.20	$48.67M	0.00%
GRNAGreenLight Biosciences Holdings	$0.30	-0.03%	-0.24	$45.43M	0.00%
KRONKronos Bio, Inc.	$0.88	+1.49%	-0.62	$53.65M	0.00%
MGTAMagenta Therapeutics, Inc.	$0.70	-7.74%	-0.02	$42.44M	0.00%

About AlloVir, Inc.

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

AlloVir, Inc. is headquartered in US.

AlloVir, Inc. (ALVR) stock trades at $9.81 with a market capitalization of $49.48M. The stock is valued at a price-to-earnings (P/E) ratio of -1.89, price-to-book of 1.41, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.96 and $24.15, and currently trades 59.4% below its 52-week high.

On profitability, AlloVir, Inc. generates a return on equity (ROE) of -72.78%, return on capital employed of -46.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.allovir.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides